Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I bought at 0,3411 in August 2019 Great Run
TRIL $24,00 NEW PRICE TARGET FROM BLOOM BURTON & Co
$TRIL VERY IMPORTANT
New Price Target for TRIL $24,00 from Bloom Burton & Co.
See the link below.
https://www.bloomburton.com/research/TRIL20200108.pdf
What is tutes?
I hope so!
We need to be positive, this stock have a great potencial to achive $2 to $4 soon.
I'm with this stock APVO because have a strong potential, Growing Revenues, a very good pipeline, price targets and analyst recommendations, and also a strong insiders buy.
Zacks 6,67 [Buy 3]
Yahoo 6,67 [Buy 1]
TipRanks 4,50 [Moderate Buy 1]
Nasdaq 3,50 to 12,00 with Consensus 4,50 [Rating 1,7 is between Buy and Strong Buy]
MarketBeat 10,16 [Buy 3]
I'm also with this stock because have a strong potencial, a very good pipeline, also a very good price targets and analyst recommendations.
Zacks 5,67 [Buy 3]
Yahoo 5,67 [Strong Buy 2 + Buy 1]
MarketScreener 5,67 [Buy 3]
Nasdaq 3,00 to 7,00 [Strong Buy 3]
MarketBeat 3,00 [Buy 1]
I'm also with this stock because have a strong potencial, a very good pipeline, also a very good price targets and analyst recommendations.
Zacks 5,67 [Buy 3]
Yahoo 5,67 [Strong Buy 2 + Buy 1]
MarketScreener 5,67 [Buy 3]
Nasdaq 3,00 to 7,00 [Strong Buy 3]
MarketBeat 3,00 [Buy 1]
When somebody speak about AVEO crash, ...AVEO allways go up.
AVEO is on the way to 6,00
AVEO Almost $2,00
AVEO is going up
AVEO Pharma (AVEO)
smarteranalyst.com
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AVEO Pharma, with a price target of $9. The company’s shares closed yesterday at $2.54.
Ramakanth wrote:
“We maintain our Buy rating on AVEO and raise our 12- month price target to $9.00 per share, up from $6.50. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.5% discount rate and 3% terminal growth rate.”
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.2% and a 35.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Currently, the analyst consensus on AVEO Pharma is a Strong Buy with an average price target of $6.33, a 149.2% upside from current levels. In a report issued on October 22, Piper Jaffray also reiterated a Buy rating on the stock with a $5 price target.
Buy LOW sell HIGH
Zacks Rank "2" BUY, 1y price target 6,33
TipRanks "Stong Buy", 1y price target 6,33 to 9,00.
Check-Cap Announces IDE Submission to FDA for Its C-Scan® System
If Approved, U.S. Pilot Study Anticipated to Commence in 4Q 2018
ISFIYA, Israel, Oct. 9, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW) (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, a preparation free screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that it has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance studies of C-Scan®. If approved, the Company plans to initiate a U.S. pilot study during the fourth quarter of 2018.
Alex Ovadia, Chief Executive Officer of Check-Cap, commented: "We are pleased to announce IDE submission for our C-Scan® System. More than 700,000 deaths occur every year as a result of colorectal cancer and more than 1.3 million new colorectal cancer incidents are identified each year. Despite evidence that colorectal cancer screening can reduce associated mortality, adherence remains low due to the required preparation, invasiveness, and limited access in some communities to the current screening methods. We look forward to completing our U.S. regulatory path approval process, commencing our U.S. pilot study later this year, and eventually bringing the C-Scan® System to people in need. This schedule aligns with our near-term goals for the remainder of 2018, as we continue to execute on our clinical and commercial plans toward 2019."
https://finance.yahoo.com/news/check-cap-announces-ide-submission-110000566.html
GE Healthcare is where is the Manufacturing line for Check Cap Capsule
https://www.mobihealthnews.com/content/israeli-government-dips-digital-health-33m-grant
Israeli government dips into digital health with $33M grant
Israel is continuing to carve out its space as a digital health hub in the Middle East. Today the Israeli government announced a $33 million grant aimed at furthering the country's foothold in digital health, specifically in biotech and medicine, according to Reuters. Medtronic, GE Healthcare, and Change Healthcare were named the three recipients of the funding; each company will get a different portion of the total amount.
The plan is for the government to give the companies their grant money over the course of the next six years as they expand their operations in Israel, Reuters reports.
“We are pleased to be collaborating with the Israeli Innovation Authority,” Medtronic wrote in an email statement to MobiHealthNews about the funding. “With facilities based in Israel, we have access to some of the best minds and most dedicated professionals in the healthcare industry.”
Israel’s interest in digital health is nothing new. In fact, the small country has seen a lot of activity from investors; in 2017 backers poured $208 million into Haifa, Israel digital health startups and $146 million into Tel-Aviv, Israel-based companies for a total of 20 deals in the country that year, according to Startup Health’s 2017 report. Emerging Israeli digital health companies include smartphone glucose meter maker Dariohealth, telehealth provider Tyto Care, and deep learning startup Zebra Medical. However, none of the companies selected for the grant are based in Israel, although some have operations in the country.
Israel's government has also shown a keen interest in digital health. It plans to invest $275 million into digitalizing every citizen's personal health records, according to a Bloomberg. The efforts are in part to expand R&D for new medications, Bloomberg reports.
The companies selected for the grant aren’t newcomers. Medtronic is one of the big names in diabetes management. The company’s Medtronic MiniMed was approved was the first FDA-approved continuous glucose monitoring system that controls automated insulin delivery via a hybrid closed-loop system. At the end of June the company announced that the product was cleared by the FDA for kids aged seven to 14 years.
GE Healthcare has been in the space for years, launching digital health products as far back as 2009 with the clearance of the ECG product, MAC 800. In more recent news, the company teamed up with Nvidia in November on an initiative to fast-track artificial intelligence adoption. The Nvidia partnership builds on GE Healthcare’s 10-year alliance with the company to bring the most sophisticated AI to GE Healthcare’s 500,000 globally deployed imaging devices and to accelerate healthcare processing.
Change Healthcare was also founded more than a decade ago in 2005. In June the company announced results of its cost-savings study. It has teamed up with high-profile companies including Microsoft, Adobe, and Blue Cross Blue Shield of Arizona on various studies.
4,20 Long also
Closed at 7,80 2017 Dec 04
FRAN Price Yargets
A) I3investor.com $16,00 upside +$8,20
B) Streetinsider.com $16,00
C) Nasdaq.com $10,00
D) Yahoo Finance $12,00
ZACKS in November 29, 2017
"FRAN" could be the Hottest Stocks of 2018?
I agree with you. What we can do for that!
Without a buyer??????
Reverse Stock Split it will be the Easter gift from PSID to the shareholders??????
Reverse Stock Split see on Form 10-K March31 2017 on page 86 /144
1:3.000 Reverse stock split
On Form 10-K March 31 2017
New Reverse Stock Split at a ratio
1: 3.000
PSID is trading in NOTC market?
The PSID 2016 full year Projection of Revenue is 5 to 6 million.
In the RedChip Research profile about PSID from July 19, 2016 you can see the Revenue projection per segment by quarter until end of 2019.
It will be tomorow because of that investors are buying today PSID shares
PSID Form 10-K with full year 2016 earnings will be on March 30, 2017.
PSID announced that in the press release when Announces 2016 Highlights
PSID Last year on January 11, they announce the 2015 Highlights and 2016 Outlook.
Maybe this week they will do the 2016 Highlights and 2017 Outlook?
Also on January 13 2015, they made a Shareholder Update.
I think great news are coming.
PSID Decreasing of Revenue
PSID Decreasing of Revenue in 2016 3ºquarter "$1.065.000" if compare with 2016 1ºquarter "$1.664.000" and compare with 2016 2ºquarter "1.848.000"
Also a decreasing of Revenue if we compare 2016 3ºquarter "1.065.000" with the 3ºquarter of 2015 "2,500.000"
Positive ID
The E-N-G Mobile Labs next event Exhibitor in:
CBRNe Convergence Congress & Exhibition,
San Diego, California, USA -
31 October - 2 November, 2016.
The most important annual congress for the global CBRNE community now in its 10th year!
Growing closer, staying distinct, merging civilian and military response to CBRN, IED and all hazard threats is the constant theme of CBRNe Convergence.
CBENe brings together expert speakers from around the globe, chosen for their insight and challenge, providing attendees with shortcuts to best practice. Streamed sessions allow you to choose presentations that best fit the needs of your organization and foster an understanding of how you can bring together civil and military forces in such fields as CBRN, EOD and hazmat to better prepare for current and future challenges. PLUS Poster presentations which outline some of the latest developments in science and technology.
http://www.cbrneworld.com/convergence2016
PositiveID Announces Highlights for Third Quarter 2016
GlobeNewswire•September 27, 2016
DELRAY BEACH, Fla., Sept. 27, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (PSID), a life sciences company focused on detection and diagnostics, announced today a summary of its highlights for the third quarter of 2016.
Highlights
• PositiveID was awarded a follow-on contract from the U.S. Department of the Interior on behalf of the U.S. Department of Homeland Security Science & Technology Directorate for the SenseNet Program Phase II, in conjunction with its partner ENSCO.
• The Company announced that it is conducting a pilot study with seqID inc using PositiveID's Firefly Dx polymerase chain reaction ("PCR") breadboard prototype pathogen detection system ("prototype system") to detect genetically modified organisms for the agricultural market.
• The Company completed its acquisition of Thermomedics Inc., the designer and marketer of the Caregiver® infrared, non-contact thermometer, which is FDA-cleared for clinical use.
• PositiveID announced that it expects to launch a Bluetooth® version of its FDA-cleared Caregiver® infrared, non-contact thermometer by early 2017, to connect wirelessly to electronic health record (EHR) systems and other hospital equipment such as patient monitoring stations.
• The Company announced that Caregiver outperformed a temporal artery thermometer in every category evaluated during a Veterans Affairs San Diego Healthcare System study of Post Anesthesia Care Unit ("PACU") patients.
• PositiveID added Paul Schaudies, Ph.D., Co-Founder and CEO of GenArraytion, to its Board of Advisors. PositiveID has successfully detected the Zika virus on its Firefly Dx prototype system using GenArraytion’s Zika assay, the first commercially available, multi-target, PCR-based molecular test to identify the Zika virus, its Aedes Aegypti MultiFLEX™ PCR test.
• During the third quarter of 2016 bookings for vehicle production and modification at the Company’s E-N-G-Mobile Systems (“ENG”) subsidiary grew approximately 170% over the quarterly average for the first two quarters of 2016.
“We continue to make strides to expand and improve operationally in all areas of our business, and we are particularly proud of the follow-on contract award we received for the second phase of the DHS SenseNet program, which, we believe, further validates our Firefly Dx technology,” stated William J. Caragol, Chairman and CEO of PositiveID. “We believe our product portfolio, which has grown significantly following our acquisitions of Thermomedics and ENG in late 2015, represents best-in-class technologies in each of the markets we serve, and are confident these acquisitions will continue to benefit our Company for the remainder of 2016 and beyond.”
PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect pathogens at the point of need. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
Caregiver is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.
E-N-G Mobile Systems (“ENG”) is a leader in the mobile laboratory market, which is a growing segment of the specialty vehicle market as concerns over food and environment contamination, and biological and chemical weapons increase. ENG has built over 400 mobile labs, more than any other specialty vehicle manufacturer, designed for chemical and biological detection, monitoring and analysis. ENG, which has been in business for almost 40 years, further differentiates itself from its competitors with its team of scientists who work in conjunction with the design engineers and shop personnel to deliver the most advanced mobile labs available.
PositiveID and seqID Conduct Pilot Study Using Firefly Dx Prototype for GMO Detection for Agricultural Market
GlobeNewswire•September 20, 2016
DELRAY BEACH, Fla. and TORONTO, Sept. 20, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (PSID), a life sciences company focused on detection and diagnostics, announced today that it is conducting a pilot study with seqID inc using PositiveID’s Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”) to detect genetically modified organisms (“GMOs”) for the agricultural market.
The goal of the pilot study with seqID is to demonstrate that Firefly Dx can successfully detect the 35S promoter gene in samples of GMO corn and soy beans. It is estimated that 80 percent of all GMO plants contain this gene and it is considered a hallmark of GMOs.
The application of using Firefly Dx to detect genetically modified corn and soybeans in a semi-quantitative analysis has significant potential value at seaports where corn and soybeans are being shipped to countries that limit the percentage of GMOs in the shipment that may be imported. Currently, all such sampling and testing is conducted in a centralized laboratory and may take as long as two weeks, potentially delaying shipment. Firefly Dx would allow a laboratory grade result within 30 minutes at “dock side,” thereby greatly speeding up the shipment time.
PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect pathogens at the point of need. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
“This is yet another example of the broad potential applications and large markets that could be better served with a rapid, point-of-need detection system like Firefly Dx,” stated William J. Caragol, Chairman and CEO of PositiveID. “From protecting first responders, rapidly identifying hospital-acquired infections, accurately detecting emerging bio-threats in remote areas, and improving the safety of the food we eat, we believe Firefly Dx has the ability revolutionize the biological testing market.”
The global market for food-safety testing is projected to reach $19.7 billion by 2018, according to a report from Global Industry Analysts (GIA). GMO testing represents the fastest-growing segment in the global food-safety testing market.
PositiveID to Launch Bluetooth Version of its Caregiver Non-Contact Thermometer by Early 2017
GlobeNewswire•September 13, 2016
DELRAY BEACH, Fla., Sept. 13, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (PSID), a life sciences company focused on detection and diagnostics, announced today that it expects to launch a Bluetooth® version of its FDA-cleared Caregiver® infrared, non-contact thermometer by early 2017. The Bluetooth-enabled Caregiver is designed to connect wirelessly to electronic health record (EHR) systems and other hospital equipment such as patient monitoring stations.
The new Caregiver Bluetooth-enabled thermometer uses the latest low energy version Bluetooth 4.0 known as “Bluetooth Smart” for maximum battery life. The standardized Bluetooth Health Thermometer profile is incorporated into Caregiver for maximum flexibility to automatically transmit measured temperature to a wide variety of hospital systems and telemedicine platforms.
Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.
“We constantly strive to improve our offerings within all of our business lines to equip our current and potential customers with the most advanced, best-in-class products,” said William J. Caragol, Chairman and CEO of PositiveID. “By maintaining a leading technological position in the temperature monitoring market with this latest Bluetooth-enabled model of Caregiver, we can help improve the standard of care for patients while simplifying the providers’ role as well.”
The global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola, according to Global Industry Analysts, Inc.
http://www.e-n-g.com/upcoming-exhibitions
Upcoming E-N-G Exhibits
By Allison Tomek
14 Aug, 2016
E-N-G is exhibiting at these upcoming conferences. Call 800-662-4522 to arrange a meeting.
Next Generation Dx, Washington DC, Aug 22-25. E-N-G President, Lyle Probst will be speaking on the Hospital Design and Renovation track. Mobile Labs: Bringing Labs to the Point of Need http://www.nextgenerationdx.com/
American Biological Safety Assoc, Grapevine, TX (near Dallas), Sept. 30-Oct. 4 http://absaconference.org/
CBRNe Convergence, an Diego, CA, Oct. 31-Nov. 3 http://www.cbrneworld.com/convergence2016
http://www.e-n-g.com/partial-customers-list
Partial Customer List
AT&T
Australia Federal Police
BAE Systems
Battelle Memorial Institute
Bechtel
Beverly Hills Police Department
CA Air Resources Board
CA Dept. of Health Services
CA Dept. of Toxic Substance Control
Cisco Systems
City of Houston
City of Los Angeles
City of Phoenix
City of San Francisco
Convergint Technologies
CT Dept. of Environmental Protection
Daimler Trucks North America
DRS ICAS
Donlen Leasing
EAI Corporation
Ericsson
Exxon Research
GA Dept. of Environmental Protection
General Dynamics, AIS
Hamilton Sundstrand
KFMB San Diego
KGO-TV San Francisco
KMAX-TV Sacramento
Korea Dept of Environment
KPHO-TV Phoenix?
KSBY San Luis Obispo
KSL-TV Salt Lake City
KSNV Las Vegas
KSTU-TV Salt Lake City
KTVU Oakland
KTVX-TV Salt Lake City
KTXL-TV Sacramento
Lawrence Livermore National Laboratory
Los Angeles Air Force Base OES
Los Angeles Dept. of Water and Power
MA Dept. of Environmental Protection
Maricopa County, AZ
Mexico Ministry of Agriculture
Nokia Siemens Network
Nuclear Waste Partnership for Waste Isolation Pilot Plant
Pacific Gas and Electric Co.
PA DOA, DEP, DHS and PA State Police
SAIC
Sandia National Laboratories
Sonoma County, CA OES
TCI International
Tennessee Valley Authority
T-Mobile
US Army (over 100 systems)
US ATF
US Customs and Border Protection
US DHS
US EPA (9 of 10 Regions plus National Laboratories)
US FBI
US Mine Safety and Health Administration
US National Guard
US Navy
Vietnam Environmental General Dept.
Vietnam Police
Washington River Protection Solutions
Verizon Wireless
ViaSat
San Mateo County OES
SAT Corp. (White Sands Missile Base and Hill Air Force Base)
Saudi Arabia KACST
SC Law Enforcement
SC Dept. of Health and Environment
DELRAY BEACH, Fla., Aug. 15, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (PSID), a life sciences company focused on detection and diagnostics, announced its financial results for the three and six months ended June 30, 2016. The Company’s Form 10-Q for the second quarter of 2016 can be found in the Investor Relations section of its website at www.psidcorp.com.
Revenue increased to $1.8 million for the three months ended June 30, 2016, up from $51 thousand for the three months ended June 30, 2015. The increased revenue is attributable to the Company’s December 2015 acquisitions of E-N-G Mobile Systems, Inc. (“ENG”), a leader in the mobile labs market, and Thermomedics Inc., which markets the FDA cleared Caregiver® non-contact thermometer. The Company’s current revenues are primarily generated from its mobile labs segment. Gross profit increased to $636,000 for the three months ended June 30, 2016, from $5,000 for the three months ended June 30, 2015, which is also attributable to the Company’s acquisitions of ENG and Thermomedics.
Revenue for the six months ended June 30, 2016 increased to $3.5 million, up from $182 thousand for the six months ended June 30, 2015. Operating loss decreased to $2.6 million for the six months ended June 30, 2016, from an operating loss of $3.4 million for the six months ended June 30, 2015. The improvement at the operating line is primarily due to higher gross profit and decreased R&D expenses for the six months ended June 30, 2016.
“We remain very encouraged by the performance of the businesses we acquired in December 2015,” stated William J. Caragol, Chairman and CEO of PositiveID. “ENG has generated the majority of our revenues year-to-date, and both ENG and our Caregiver business have strong and improving pipelines and backlog."
“We are working on several exciting opportunities for Caregiver that could yield significant growth for this product in the second half of this year and beyond,” continued Caragol. “Last but not least, within our molecular diagnostics business we also continue to advance the lab testing of our Firefly Dx prototype system, with a target of having fieldable handheld prototypes in the second half of 2017,” concluded Caragol.
Firefly Dx is a point-of-need, handheld system that uses real-time PCR (polymerase chain reaction) chemistry that is designed to deliver molecular diagnostic results from a sample in less than 30 minutes, compared to hours or even days for a lab device. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
PositiveID’s ENG business is a leader in engineering and producing its proprietary MobiLab™ Systems, mobile labs for biological, chemical, radiological and nuclear testing applications. Over 400 ENG MobiLabs are in operation throughout the world. ENG was the first company to install gas chromatography in a mobile lab, and is a pioneer in developing mobile platforms that allow standard laboratory-grade instruments to be operated successfully in the field.
The Company’s Caregiver® is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that can offer savings of $250 or more per year per device in probe cover supplies alone.
Dr. R. Paul Schaudies of GenArraytion and the PositiveID Corporation Collaboration Will Lead to New Innovation in the Disease Detection Technology Field
Posted on August 3, 2016 by Stuart Smith
Dr. R. Paul Schaudies of GenArraytion and PositiveID Corporation (OTC:PSID) have announced collaborative plans that could help bring even more innovation to disease detection technology. Dr. Schaudies will join PositiveID’s advisory board, offering his expertise on a variety of related matters. Dr. Schaudies has previously worked with the corporation, assisting with the successful detection of the Zika virus through PositiveID’s Firefly Dx prototype real-time, point-of-need pathogen detection system. The team’s research is more relevant now than ever with concerns about the virus spreading around the world and its devastating effects.
It is estimated that 1.65 million mothers in Latin American countries could be infected with the Zika virus while they are pregnant. This could lead to tens of thousands of cases of Zika transmission from mother to child. While numbers related to the amount of Zika infections have previously been vague, The University of Notre Dame and the University of Southampton in Britain found that the number of infected mothers could even be as high as 2 million.
Researchers explain that Zika-transmitting mosquitoes have infected up to 75 percent of the human population in a given area within a year. This could be the continuation of a Zika epidemic that would spread to most of the world. The Zika virus is known for causing severe birth defects and brain damage in infected infants, including microcephaly and nerve issues.
PositiveID Corporation is a life sciences company that emphasizes early detection through portable diagnostics. The company designs equipment that allows emergency medical workers to obtain lab-quality results in a field setting. This could make virus detection faster and easier, which is important when dealing with a disease epidemic and crowds. PositiveID has previously worked with Dr. Schaudies on the Firefly Dx prototype, a portable pathogen detection system under development that is designed to offer virus detection in minutes instead of hours or days. The Firefly Dx prototype proved successful at detecting the Zika virus using GenArraytion’s assay.
In cooperation with Dr. Schaudies and the GenArraytion MultiFLEX molecular assay detection system, PositiveID was able to identify such viruses as dengue fever, Chikungunya, Zika and yellow fever. All four viruses are transmitted by the same type of mosquito. The Firefly Dx is a handheld detection system, which makes it easier for health workers to test individuals in large settings, such as the Brazilian Olympic Games. When taking a large number of people to a medical facility for pathogen testing is impractical, handheld devices allow infected individuals to be identified and quarantined for public safety. Such early detection systems could drastically reduce the rate at which an epidemic spreads.
Having the ability to quickly identify bio-threats offers other applications in the world health community as well. The Firefly Dx system is being designed to make containment of bio-threats faster, easier and safer for health workers and the public. Because Zika poses such a severe threat to pregnant women and infants, it is crucial for those infected to be diagnosed as soon as possible. The more cases of Zika that are detected and quarantined, the fewer women will become infected.
The partnership between Dr. Schaudies and PositiveID is expected to have a significant impact on PositiveID and its continued development and testing of Firefly Dx. With an experienced scientist like Dr. Schaudies taking on an advisory role, PositiveID will have even more expertise on-hand when it comes to developing new technologies and addressing world health crises such as the Zika virus. Other serious health issues such as Chikungunya could also be contained more effectively through the use of the innovative technology developed through this partnership.
GenArraytion’s Zika assay has received significant attention from the press around the world, which helps bring attention to the important issue of Zika testing. With the two Zika virus tests Dr. Schaudies has developed, researchers have a much greater chance of accurately detecting the virus both in the field in response situations and before it spreads widely to human populations. While most adults who are infected with the Zika virus experience flu-like symptoms and are not likely to face fatal complications, the rate of infant mortality and life-long birth defects in infants who are infected makes this one of the most serious health crises facing the world.
With the location of the next Olympic Games in Brazil, an area that has been significantly affected by Zika, the world is looking to PositiveID and experts such as Dr. Schaudies to provide the innovative technology solutions necessary to quell an epidemic. Technologies such as Firefly Dx are working to put the resources of a laboratory into the hands of medical professionals and first responders around the world.
About the Author
Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/
PositiveID Corporation Discusses Detection of Zika Virus on its Firefly Dx Prototype System in New Interview with SmallCapVoice.com
GlobeNewswire•August 10, 2016
AUSTIN, Texas, Aug. 10, 2016 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. today announced it conducted a new audio interview with PositiveID Corporation (“PositiveID” or the “Company”) (PSID), a life sciences company focused on detection and diagnostics. In the interview, which can be heard at http://smallcapvoice.com/blog/8-8-16-smallcapvoice-interview-with-positiveid-corporation-psid, Lyle L. Probst, President of PositiveID, discusses the Company’s successful detection of Zika virus on its Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”).
PositiveID used assay partner GenArraytion, Inc.’s Aedes Aegypti MultiFLEX™ PCR test, which targets four genetic regions of the Zika virus, on PositiveID’s Firefly Dx prototype system. PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect bio-threats at the point of need. Currently, PCR tests are run on large lab equipment and take a minimum of four hours to deliver results. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test.
The Firefly Dx prototype system has also successfully detected a number of other pathogenic organisms including E.coli, Ebola, influenza, MRSA, MSSA, C. diff and others.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About PositiveID Corporation
PositiveID Corporation is a life sciences company focused on detection and diagnostics, with an extensive patent portfolio. PositiveID specializes in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.